Clinical Trials Logo

Anti-MAG Neuropathy clinical trials

View clinical trials related to Anti-MAG Neuropathy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04568174 Terminated - Anti-MAG Neuropathy Clinical Trials

First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy

Start date: November 17, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, the new drug called PPSGG (PN-1007) will be tested. Preliminary studies conducted in animals suggest PPSGG (PN-1007) might be a good treatment for reducing levels of anti-MAG antibodies in patients with anti-MAG neuropathy. This is the first research of PPSGG (PN-1007) in people and its main purpose is to test its safety and acceptability in patients. In this study it will be examined how the drug is changed by and removed from the body and checked for signs that the drug may be truly effective against anti-MAG neuropathy. PPSGG (PN-1007) will be tested at several different doses.